EMVision Medical Devices (EMV) AGM 2025 Presentation summary

Mission and technology

• Aims to reduce global stroke and traumatic brain injury burden with two portable brain scanning devices targeting unmet clinical needs.

• Over $60m invested in 15+ years of R&D in novel radio frequency imaging technology from the University of Queensland.

• Devices are portable, non-ionizing, and designed for rapid neurodiagnostics in diverse settings.

• Multi-billion dollar market opportunity in stroke care, with expansion planned for traumatic brain injury.

• 300-patient pre-validation trial met primary endpoints, supporting pivotal trial for FDA clearance.

Leadership and team

• Executive team includes experienced leaders in medical device development, commercialization, and regulatory affairs.

• Board features former CEOs and executives from major healthcare and medical device organizations.

• Team has expertise in capital markets, product design, and clinical operations.

Recent highlights and clinical progress

• Successful aeromedical volunteer testing and pivotal trial site activations at major US and Australian hospitals.

• $5m government grant awarded to accelerate First Responder commercialisation.

• 'EMView' study showed 92% sensitivity and 85% specificity for haemorrhage detection; ischaemia detection improved to 95% sensitivity and 80% specificity.

• $12m placement and $2m SPP completed; additional $3m grant for telehealth-enabled device study.